Eversept Partners, LP
- SEC CIK
- 0001697013
- Latest filing
- Aug 14, 2026
CLDX holding history
Celldex Therapeutics, Inc. in every 13F filed by Eversept Partners, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CLDX overviewAll 13F holders of CLDXFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,785,941
- Value
- $66.5M
- % of portfolio
- 3.6%
- Quarters held
- 19
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,785,941 | $66.5M | 3.6% | −2,075−0.1% | Reduced | Holders |
| Q1 2026 | 1,788,016 | $56.7M | 3.7% | +353,291+24.6% | Added | Holders |
| Q4 2025 | 1,434,725 | $39.0M | 2.2% | +280,805+24.3% | Added | Holders |
| Q3 2025 | 1,153,920 | $29.9M | 2.3% | +315,184+37.6% | Added | Holders |
| Q2 2025 | 838,736 | $17.1M | 1.7% | +142,237+20.4% | Added | Holders |
| Q1 2025 | 696,499 | $12.6M | 1.4% | −23,337−3.2% | Reduced | Holders |
| Q4 2024 | 719,836 | $18.2M | 1.9% | +154,934+27.4% | Added | Holders |
| Q3 2024 | 564,902 | $19.2M | 1.5% | −68,113−10.8% | Reduced | Holders |
| Q2 2024 | 633,015 | $23.4M | 1.8% | −78,100−11.0% | Reduced | Holders |
| Q1 2024 | 711,115 | $29.8M | 2.2% | −42,992−5.7% | Reduced | Holders |
| Q4 2023 | 754,107 | $29.9M | 2.9% | +165,964+28.2% | Added | Holders |
| Q3 2023 | 588,143 | $16.2M | 1.8% | −197,597−25.1% | Reduced | Holders |
| Q2 2023 | 785,740 | $26.7M | 2.8% | +96,064+13.9% | Added | Holders |
| Q1 2023 | 689,676 | $24.8M | 2.2% | +130,902+23.4% | Added | Holders |
| Q4 2022 | 558,774 | $24.9M | 2.4% | −67,598−10.8% | Reduced | Holders |
| Q3 2022 | 626,372 | $17.6M | 2.1% | +73,984+13.4% | Added | Holders |
| Q2 2022 | 552,388 | $14.9M | 1.5% | −84,065−13.2% | Reduced | Holders |
| Q1 2022 | 636,453 | $21.7M | 2.0% | +43,975+7.4% | Added | Holders |
| Q4 2021 | 592,478 | $22.9M | 1.9% | +592,478 | New | Holders |